by Elena Iemma | Nov 13, 2023 | Blog
This is a two-way street Hey Hey, Hallo, Hola, Ciao, Namaste, Hello, Bonjour, Konnichiwa! When do you do your “thinking” about the day? Do you do it while running? I do! And lately, I’ve been thinking about AI and Human Intelligence in vaccine development—how far...
by Elena Iemma | Oct 24, 2023 | Blog
Amsterdam Immunogenicity and Tolerance Seminar: Join EpiVax in Amsterdam Before we get to the scary stuff, have you registered for the 9th annual Amsterdam Immunogenicity and Tolerance Seminar yet? This flagship immunology conference brings together global leaders in...
by Elena Iemma | Sep 24, 2023 | Blog
Welcome to Tokyo! Yes, it’s true — EpiVax is in Japan for the Tokyo Immunogenicity Seminar! Sarah Moniz, Guilhem Richard (CTO of EpiVax Therapeutics), and I arrived Friday and have been exploring Tokyo landmarks all weekend. We’re thrilled to reconnect with friends...
by Elena Iemma | Aug 20, 2023 | Blog
Immunogenicity Assessment of Peptide Drugs: PANDA Paper and Retatrutide Insights RIP Sinead. She was Fearless. She was irreverent. She risked her career to speak out about sexual abuse. She sang with real, raw, emotion. She showed up, and she stood up. She...
by Elena Iemma | Aug 10, 2023 | News
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M...
